Mount Sinai Launches Pilot Study on Chemotherapy vs. Surgery for Stage II/III Rectal Cancer
The Quicksilver II pilot study will evaluate if patients with margin-clear Stage II or III rectal cancer can safely skip neo-adjuvant chemotherapy.
Phase III
rectal cancer patients
Status
Initiated
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The Quicksilver II pilot study has the potential to redefine treatment standards for Stage II/III rectal cancer by evaluating the feasibility of skipping neo-adjuvant chemotherapy. A successful outcome could shift the competitive landscape, impacting companies focused on current treatment paradigms.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor results from the pilot study and subsequent funding announcements for the larger efficacy trial.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.